{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T20:12:10Z","timestamp":1785787930115,"version":"3.56.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T00:00:00Z","timestamp":1772150400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2,27]]},"abstract":"<jats:p>Uganda implemented the antiretroviral therapy (ART) optimization program in July 2019, based on an eligibility rule. ART optimization targeted individuals with prior viral load (VL)\u2005&lt;\u20051000 copies\/mL, while those with VL\u2005\u2265\u20051000 copies\/mL continued with non-optimized regimens. We assessed the effectiveness of ART optimization on VL suppression among children and adolescents with HIV (CAWH) in Uganda. We also assessed the compliance of human immunodeficiency virus (HIV) clinics with the eligibility rule and its effect on ART optimization. Therefore, we designed a quasi-experimental study using data from 21 urban and rural HIV clinics. The exposure was ART optimization, defined as the initiation or transition of CAWH on dolutegravir or a protease inhibitor (boosted lopinavir). Children and adolescents with HIV on an optimized ART regimen formed the exposed group, while those on a non-optimized ART regimen comprised the nonexposed group. The primary outcome was VL suppression, defined by VL\u2005&lt;\u20051000 copies\/mL after \u22656 months of ART optimization. We assessed the effectiveness of ART optimization on VL suppression using 2-stage least squares instrumental variable regression due to imperfect compliance with the eligibility rule across the clinics. We also established the effectiveness of the eligibility rule on ART optimization for individuals just below and just above the cutoff. Sensitivity analysis was performed using a noncausal approach. We analyzed data from 2999 CAWH aged \u226419 years and found an overall VL suppression of 76.1% (2282\/2999). We found that ART optimization showed a trend toward improved VL suppression (risk ratio [RR] 1.81, 95% CI: 0.79\u20134.14). However, compliance with the rule was only for 2.6% of the participants, and the rule did not improve ART optimization (RR 0.96, 95% CI: 0.88\u20131.05). Overall, ART optimization, guided by an eligibility rule, did not achieve the target of \u226595% VL suppression among CAWH across the 21 public HIV clinics in Uganda, partly due to low compliance with the rule, although it showed a trend toward improvement. Addressing context-specific biological, behavioral, social, and structural barriers is needed to optimize VL outcomes.<\/jats:p>","DOI":"10.1097\/md.0000000000047862","type":"journal-article","created":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T01:01:22Z","timestamp":1772240482000},"page":"e47862","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of ART optimization on viral load suppression in children and adolescents with HIV in Uganda: A quasi-experimental study"],"prefix":"10.1097","volume":"105","author":[{"given":"Esther M","family":"Nasuuna","sequence":"first","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"},{"name":"Non-communicable Diseases Program, Medical Research Council\/Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Babirye","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanita","family":"Kigozi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Muganzi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9065-0389","authenticated-orcid":false,"given":"Jonathan","family":"Izudi","sequence":"additional","affiliation":[{"name":"Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda"},{"name":"Department of Community Health, Mbarara University of Science and Technology, Mbarara, Uganda"},{"name":"Directorate of Graduate Training, Research and Innovation, Muni University, Arua, Uganda."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R5-20260413","doi-asserted-by":"crossref","first-page":"e766","DOI":"10.1016\/S2352-3018(21)00265-4","article-title":"Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries.","volume":"8","author":"Han","year":"2021","journal-title":"Lancet HIV"},{"key":"R6-20260413","doi-asserted-by":"crossref","first-page":"e33737","DOI":"10.1097\/MD.0000000000033737","article-title":"Viral suppression in the era of transition to dolutegravir-based therapy in Cameroon: children at high risk of virological failure due to the lowly transition in pediatrics.","volume":"102","author":"Fokam","year":"2023","journal-title":"Medicine (Baltimore)"},{"key":"R8-20260413","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12913-019-3963-y","article-title":"Challenges faced by caregivers of virally non-suppressed children on the intensive adherence counselling program in Uganda: a qualitative study.","volume":"19","author":"Nasuuna","year":"2019","journal-title":"BMC Health Serv Res"},{"key":"R9-20260413","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/QAD.0000000000002454","article-title":"Challenges to achieving and maintaining viral suppression among children living with HIV.","volume":"34","author":"Kakkar","year":"2020","journal-title":"AIDS"},{"key":"R10-20260413","doi-asserted-by":"crossref","first-page":"e25970","DOI":"10.1002\/jia2.25970","article-title":"Effectiveness and safety of dolutegravir and raltegravir for treating children and adolescents living with HIV: a systematic review.","volume":"25","author":"Townsend","year":"2022","journal-title":"J Int AIDS Soc"},{"key":"R11-20260413","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa2108793","article-title":"Dolutegravir as first-or second-line treatment for HIV-1 infection in children.","volume":"385","author":"Turkova","year":"2021","journal-title":"N Engl J Med"},{"key":"R13-20260413","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/jech-2022-219267","article-title":"Causal inference and effect estimation using observational data.","volume":"76","author":"Igelstr\u00f6m","year":"2022","journal-title":"J Epidemiol Community Health"},{"key":"R14-20260413","doi-asserted-by":"crossref","first-page":"e0002240","DOI":"10.1371\/journal.pgph.0002240","article-title":"Impact of intensive adherence counseling on viral load suppression and mortality among people living with HIV in Kampala, Uganda: a regression discontinuity design.","volume":"3","author":"Izudi","year":"2023","journal-title":"PLOS Global Public Health"},{"key":"R15-20260413","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1213\/ANE.0000000000002787","article-title":"Five steps to successfully implement and evaluate propensity score matching in clinical research studies.","volume":"127","author":"Staffa","year":"2018","journal-title":"Anesth Analg"},{"key":"R16-20260413","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1002\/pds.4158","article-title":"A tutorial on the use of instrumental variables in pharmacoepidemiology.","volume":"26","author":"Ertefaie","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R17-20260413","doi-asserted-by":"crossref","first-page":"e37175","DOI":"10.1097\/MD.0000000000037175","article-title":"No potential causal link between HP infection and IBD: a 2way Mendelian randomization study.","volume":"103","author":"Yang","year":"2024","journal-title":"Medicine (Baltimore)"},{"key":"R18-20260413","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12874-025-02553-x","article-title":"Causal inference methodologies to assess the effect of missed clinic visits on treatment success rate among people with tuberculosis in rural Uganda.","volume":"25","author":"Izudi","year":"2025","journal-title":"BMC Med Res Methodol"},{"key":"R19-20260413","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.jclinepi.2014.06.021","article-title":"Regression discontinuity designs are underutilized in medicine, epidemiology, and public health: a review of current and best practice.","volume":"68","author":"Moscoe","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"R20-20260413","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1097\/CORR.0000000000000729","article-title":"Statistics in brief: instrumental variable analysis: an underutilized method in orthopaedic research.","volume":"477","author":"Huang","year":"2019","journal-title":"Clin Orthop Relat Res"},{"key":"R21-20260413","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.jclinepi.2022.06.022","article-title":"A gentle introduction to instrumental variables.","volume":"149","author":"Widding-Havneraas","year":"2022","journal-title":"J Clin Epidemiol"},{"key":"R22-20260413","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.4269\/ajtmh.24-0630","article-title":"Effect of active follow-up on viral load suppression among people living with HIV on intensive adherence counseling in Uganda: an instrumental variable analysis.","volume":"112","author":"Izudi","year":"2025","journal-title":"Am J Trop Med Hyg"},{"key":"R24-20260413","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2105\/AJPH.94.3.361","article-title":"Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement.","volume":"94","author":"Des Jarlais","year":"2004","journal-title":"Am J Public Health"},{"key":"R25-20260413","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1097\/INF.0000000000004037","article-title":"Virologic outcomes and ARV switch profiles 2 Years after national rollout of dolutegravir to children less than 15 years in Southern Mozambique.","volume":"42","author":"Gill","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"R26-20260413","first-page":"229","article-title":"Effect of dolutegravir and multimonth dispensing on viral suppression among children with HIV.","volume":"93","author":"Mugo","year":"2023","journal-title":"JAIDS (1999)"},{"key":"R27-20260413","doi-asserted-by":"crossref","first-page":"23259582221109613","DOI":"10.1177\/23259582221109613","article-title":"Adherence, effectiveness and safety of dolutegravir based antiretroviral regimens among HIV infected children and adolescents in Tanzania.","volume":"21","author":"Mutagonda","year":"2022","journal-title":"J Int Assoc Providers AIDS Care (JIAPAC)"},{"key":"R28-20260413","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/aid.2022.0039","article-title":"Integrase strand transfer inhibitor use in children with perinatal HIV-1 infection: a narrative review.","volume":"39","author":"Failla","year":"2023","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R29-20260413","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/hiv.12752","article-title":"Similar efficacy and safety of dolutegravir between age groups of HIV\u20101\u2010infected paediatric and young adult patients aged 5 years and older.","volume":"20","author":"Frange","year":"2019","journal-title":"HIV Med"},{"key":"R30-20260413","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/INF.0000000000003878","article-title":"Realizing the promise of dolutegravir in effectively treating children and adolescents living with HIV in real-world settings in 6 countries in Eastern and Southern Africa.","volume":"42","author":"Bacha","year":"2023","journal-title":"Pediatr Infect Dis J"},{"key":"R31-20260413","doi-asserted-by":"crossref","first-page":"e0288619","DOI":"10.1371\/journal.pone.0288619","article-title":"Optimizing antiretroviral therapy for children living with HIV: experience from an observational cohort in Lesotho.","volume":"18","author":"Tukei","year":"2023","journal-title":"PLoS One"},{"key":"R32-20260413","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-018-6048-7","article-title":"\u201cHow am I going to live?\u201d: exploring barriers to ART adherence among adolescents and young adults living with HIV in Uganda.","volume":"18","author":"MacCarthy","year":"2018","journal-title":"BMC Public Health"},{"key":"R33-20260413","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1007\/s10461-020-02822-4","article-title":"Interventions to improve antiretroviral therapy adherence among adolescents and youth in low-and middle-income countries: a systematic review 2015\u20132019.","volume":"24","author":"Reif","year":"2020","journal-title":"AIDS Behav"},{"key":"R34-20260413","first-page":"198","article-title":"Initiation of dolutegravir vs. efavirenz on 12- and 24-month retention and viral suppression: a target trial emulation.","volume":"58","author":"Zheng","year":"2025","journal-title":"Infect Dis (London, England)"},{"key":"R35-20260413","first-page":"151","article-title":"Initiation of dolutegravir versus efavirenz on viral suppression and retention at 6 months: a regression discontinuity design.","volume":"99","author":"Zheng","year":"2025","journal-title":"JAIDS (1999)"},{"key":"R36-20260413","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12889-020-09717-y","article-title":"Psychosocial support interventions for improved adherence and retention in ART care for young people living with HIV (10\u201324 years): a scoping review.","volume":"20","author":"Okonji","year":"2020","journal-title":"BMC Public Health"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047862","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:17:32Z","timestamp":1785784652000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000047862"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,27]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000047862","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,27]]},"assertion":[{"value":"2024-04-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-09","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}